287 filings
Page 3 of 15
8-K
ALNAQ
Allena Pharmaceuticals, Inc.
23 Dec 21
Entry into a Material Definitive Agreement
6:08am
424B5
ALNAQ
Allena Pharmaceuticals, Inc.
23 Dec 21
Prospectus supplement for primary offering
6:07am
424B5
ALNAQ
Allena Pharmaceuticals, Inc.
23 Dec 21
Prospectus supplement for primary offering
6:05am
UPLOAD
ALNAQ
Allena Pharmaceuticals, Inc.
19 Nov 21
Letter from SEC
12:00am
4
Brenner Louis MD
17 Nov 21
Allena Pharmaceuticals / LOUIS MD BRENNER ownership change
5:00pm
10-Q
2021 Q3
ALNAQ
Allena Pharmaceuticals, Inc.
Quarterly report
12 Nov 21
4:08pm
CORRESP
ALNAQ
Allena Pharmaceuticals, Inc.
12 Nov 21
Correspondence with SEC
12:00am
8-K
ALNAQ
Allena Pharmaceuticals, Inc.
10 Nov 21
Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress
4:07pm
UPLOAD
ALNAQ
Allena Pharmaceuticals, Inc.
29 Oct 21
Letter from SEC
12:00am
8-K
ALNAQ
Allena Pharmaceuticals, Inc.
29 Sep 21
Other Events
8:42am
8-K
ALNAQ
Allena Pharmaceuticals, Inc.
27 Aug 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:01pm
10-Q
2021 Q2
ALNAQ
Allena Pharmaceuticals, Inc.
Quarterly report
12 Aug 21
4:16pm
8-K
ALNAQ
Allena Pharmaceuticals, Inc.
10 Aug 21
Allena Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Corporate Progress
4:05pm
8-K
ALNAQ
Allena Pharmaceuticals, Inc.
16 Jul 21
Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:22pm
424B5
ALNAQ
Allena Pharmaceuticals, Inc.
15 Jul 21
Prospectus supplement for primary offering
4:55pm
8-K
ALNAQ
Allena Pharmaceuticals, Inc.
13 Jul 21
Allena Pharmaceuticals Provides Update on Clinical Development Programs
8:52am
8-K
ALNAQ
Allena Pharmaceuticals, Inc.
4 Jun 21
Amendments to Articles of Incorporation or Bylaws
4:01pm